FDAnews
www.fdanews.com/articles/82445-mivt-s-proprietary-stent-coating-technology-completes-major-long-term-animal-study-with-excellent-results

MIVT'S PROPRIETARY STENT COATING TECHNOLOGY COMPLETES MAJOR LONG-TERM ANIMAL STUDY WITH EXCELLENT RESULTS

November 15, 2005

MIV Therapeutics, a leading developer of new generation biocompatible coatings and advanced drug delivery systems, recently announced that a pivotal long-term animal study of its novel stent coating technology has been concluded, with results that were unequivocally successful in demonstrating the coating's excellent biocompatibility and safety. The 6-month study, performed by Center for Research in Cardiovascular Interventions of the Methodist Hospital Research Institute, an independent research organization, indicated that MIVT's Hydroxyapatite-based coatings were excellent candidates for advanced drug-eluting stent coatings.
Business Wire